Antigen Affinity Purified Polyclonal Antibodies

Anti-Human IFN-β

Product Details

Catalogue Number: 500-P32B

Source: Polyclonal Rabbit

Preparation: Produced from sera of rabbits immunized with highly pure Recombinant Human IFN-beta. Anti-Human IFN-beta-specific antibody was purified by affinity chromatography employing immobilized Human IFN-beta matrix.

Immunogen: E.coli derived Recombinant Human IFN-β (PeproTech catalog# 300-02B)*
*Catalog# 300-02B has been replaced with 300-02BC.

Sandwich ELISA: To detect Human IFN-β by sandwich ELISA (using 100 μl/well antibody solution) a concentration of 0.5 - 2.0 μg/ml of this antibody is required. This antigen affinity purified antibody, in conjunction with PeproTech’s Biotinylated Anti-Human IFN-β (500-P32BBt) as a detection antibody, allows the detection of at least 0.2 - 0.4 ng/well of recombinant Human IFN-β.

Anti-Human IFN-β Sandwich ELISA

Western Blot: To detect Human IFN-β by Western Blot analysis this antibody can be used at a concentration of 0.1-0.2 µg/ml. When used in conjunction with compatible secondary reagents, the detection limit for recombinant Human IFN-β is 1.5-3.0 ng/lane, under either reducing or non-reducing conditions.

Anti-Human IFN-β Western Blot Reduced Anti-Human IFN-β Western Blot Unreduced

Note:

Additional applications tested on a lot-to-lot basis. Please contact Technical Support for more information.

crossreactivity:
Country Of Origin: USA

Not for human use.

Research Interest

product.subtitle.recentcitations

First Author
Gozgit, J M
Title
PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity.
Citation
Cancer Cell; 39(9) pg1214-1226.e10
PubMed Id
First Author
Kölle, J
Title
Respiratory infections regulated blood cells IFN-β-PD-L1 pathway in pediatric asthma.
Citation
Immunity, Inflammation and Disease; 8(3) pg310-319
PubMed Id
First Author
Liu, Y
Title
STAT3/p53 pathway activation disrupts IFN-β-induced dormancy in tumor-repopulating cells.
Citation
The Journal of Clinical Investigation; 128(3) pg1057-1073
PubMed Id